Zentalis Pharmaceuticals
Update in progressZNTL (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule cancer therapies in the United States. It develops azenosertib, in Phase 3 for ovarian cancer and other tumors, and ZN‑c3‑001, a Phase 1 study of azenosertib as monotherapy in solid tumors. MAMMOTH (ZN‑c3‑006) tests azenosertib in PARP-inhibitor–resistant ovarian cancer (Phase 1/2). It has a licensing relationship with Recurium IP Holdings and was founded in 2014 in San Diego.
Company score
- Sentiment
- -0.48
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.13
- Governance
- -0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMs. Julie M. Eastland M.B.A.
- Founded2014
- Employees106
- Websitezentalis.com
Identifiers
- ISINUS98943L1070
- FIGIBBG00R2K8TF5
- CUSIP98943L107
- CIK0001725160